ACSL3 and prostate cancer: ACSL3 expression was greater than that of matching normal tissue in the CHOL (bile duct cancer), COAD (colon cancer), LIHC (liver cancer), PRAD (prostate cancer), and STAD (stomach cancer), but was decreased in the KIRC (kidney clear cell carcinoma), KIRP (kidney papillary cell carcinoma), and THCA (thyroid cancer) (P < 0.05) (Figure 1).